论文部分内容阅读
美国Oravax公司就利用黄热病疫苗抵抗其他病毒的嵌合疫苗技术从圣路易斯大学取得了全球专有权.该技术将为Oravax公司的Chimerivax类疫苗提供机会.这类疫苗将靶病毒的抗原编码基因与黄热病YF17D疫苗株病毒复制所需的基因结合.该疫苗保留了黄热病疫苗的安全性和免疫能力,但诱导的免疫应答则对靶病毒具有特异性.研究人员用Chimerivax技术制备出实验性乙型脑炎疫苗,单剂接种动物模型可诱导高水平保护作用.另一项临床前试验将确定该疫苗的药理学和毒理学作用,从而为人体试验提供依据.预期1999年将开始临床试验.
Oravax, a US company, has acquired global patent rights from St. Louis University for its chimeric vaccine technology that uses yellow fever vaccines against other viruses, providing the opportunity for Oravax’s Chimerivax-based vaccines that target the antigenic-encoding genes Which binds to the genes required for the replication of the YF17D vaccine strain of yellow fever Y. The vaccine retains the safety and immunogenicity of the yellow fever vaccine but the induced immune response is specific for the target virus.The researchers prepared using Chimerivax technology Experimental encephalitis vaccine, a single dose vaccination animal model can induce high levels of protection Another preclinical trial will determine the pharmacological and toxicological effects of the vaccine, providing a basis for human trials is expected to begin in 1999 Clinical Trials.